FDA
-
-
-
-
-
-
-
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
-
-
-
-
-
-
-
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
-
-
-
-
-
-
-
FDA approves first Menkes disease treatment for pediatric patients
-
-
-
-
-
-
-
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
-
-
-
-
-
-
-
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
-
-
-
-
-
-
-
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
-
-
-
-
-
-
-
Journey Medical Corp (DERM) Announces Emrosi Data Analysis to be Presented at SDPA
-
327,817 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

